Monday, June 18, 2018

Bone Marrow Transplantation - Table of Contents alert Volume 53 Issue n6

If you are unable to see the message below, click here to view.
Bone Marrow Transplantation

Volume 53, Issue 6

In this issue
Review Article
Also new


Detection of secondary malignancy following high-dose chemotherapy in germ cell tumors: prospects and limitations

Moussab Damlaj & Shahrukh K. Hashmi

Bone Marrow Transplantation 2018 53 :661 - 663; January 30, 2018; 10.1038/s41409-018-0101-0


Abstract | Full Text

Review Article

Prevention and treatment of relapse after stem cell transplantation with immunotherapy

Nicola Gökbuget, Jonathan Canaani, Arnon Nagler, Michael Bishop, Nicolaus Kröger et al.

Bone Marrow Transplantation 2018 53 :664 - 672; May 24, 2018; 10.1038/s41409-018-0232-3


Abstract | Full Text


Impaired thymopoiesis predicts for a high risk of severe infections after reduced intensity conditioning without anti-thymocyte globulin in double umbilical cord blood transplantation

Lucia E. Duinhouwer, Nick Beije, Bronno van der Holt, Anita Rijken-Schelen, Cor H. Lamers et al.

Bone Marrow Transplantation 2018 53 :673 - 682; February 09, 2018; 10.1038/s41409-018-0103-y


Abstract | Full Text

AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation

Kazimierz Halaburda, Myriam Labopin, Mohamed Houhou, Dietger Niederwieser, Jürgen Finke et al.

Bone Marrow Transplantation 2018 53 :683 - 691; April 18, 2018; 10.1038/s41409-018-0165-x


Abstract | Full Text

Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome

Richard K. Burt, Xiaoqiang Han, Paula Gozdziak, Kim Yaung, Amy Morgan et al.

Bone Marrow Transplantation 2018 53 :692 - 700; May 31, 2018; 10.1038/s41409-018-0173-x


Abstract | Full Text

Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma

Jennifer Huang, Sharon Phillips, Michael Byrne, Wichai Chinratanalab, Brian G. Engelhardt et al.

Bone Marrow Transplantation 2018 53 :701 - 707; April 27, 2018; 10.1038/s41409-018-0177-6


Abstract | Full Text

Impact of body mass index at different transplantation stages on postoperative outcomes in patients with hematological malignancies: a meta-analysis

Guangxu Ren, Wei Cai, Liping Wang, Jiazhang Huang, Suqin Yi et al.

Bone Marrow Transplantation 2018 53 :708 - 721; May 24, 2018; 10.1038/s41409-018-0234-1


Abstract | Full Text

Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT)

Andrea Necchi, Salvatore Lo Vullo, Simona Secondino, Giovanni Rosti, Manuela Badoglio et al.

Bone Marrow Transplantation 2018 53 :722 - 728; January 24, 2018; 10.1038/s41409-017-0079-z


Abstract | Full Text

HLA mismatches that are identical for the antigen recognition domain are less immunogenic

Dave Roelen, Yvonne de Vaal, Cynthia Vierra-Green, Stephanie Waldvogel, Stephen Spellman et al.

Bone Marrow Transplantation 2018 53 :729 - 740; February 06, 2018; 10.1038/s41409-018-0108-6


Abstract | Full Text

Analysis of the Spanish CCR5-∆32 inventory of cord blood units: lower cell counts in homozygous donors

Emma Enrich, Francisco Vidal, Francisco Sánchez-Gordo, Juan M. Gómez-Zumaquero, Antonio Balas et al.

Bone Marrow Transplantation 2018 53 :741 - 748; February 06, 2018; 10.1038/s41409-018-0114-8


Abstract | Full Text

Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC

Karine Augeul-Meunier, Marie-Lorraine Chretien, Anne-Marie Stoppa, Lionel Karlin, Lofti Benboubker et al.

Bone Marrow Transplantation 2018 53 :749 - 755; March 09, 2018; 10.1038/s41409-018-0122-8


Abstract | Full Text

Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older

Zain A. Bashey, Xu Zhang, Stacey Brown, Katelin Jackson, Lawrence E. Morris et al.

Bone Marrow Transplantation 2018 53 :756 - 763; March 09, 2018; 10.1038/s41409-018-0126-4


Abstract | Full Text


Use of split peripheral blood stem cell harvests in myeloma identifies functional preservation of progenitor cells cryopreserved for several years and demonstrates no functional damage to the bone marrow microenvironment

Michael John Watts, Stuart James Ings, Jude Dorman, Neil Rabin & David Christopher Linch

Bone Marrow Transplantation 2018 53 :764 - 765; February 12, 2018; 10.1038/s41409-018-0121-9


Abstract | Full Text

Clinical-scale manufacturing of γδ T cells for protection against infection and disease recurrence following haploidentical peripheral blood stem cell transplantation and cyclophosphamide gvhd prophylaxis

Lawrence S. Lamb, Sailesh Pillai, Samantha Langford, Joscelyn Bowersock, Antonio Di Stasi et al.

Bone Marrow Transplantation 2018 53 :766 - 769; March 07, 2018; 10.1038/s41409-018-0130-8


Abstract | Full Text

Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis

Yao Chen, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Feng-Rong Wang et al.

Bone Marrow Transplantation 2018 53 :770 - 773; May 03, 2018; 10.1038/s41409-018-0175-8


Abstract | Full Text

Does marital status affect the outcomes after allogeneic hematopoietic cell transplantation?

Tomoko Sato, Takaaki Konuma, Maki Oiwa-Monna, Susumu Tanoue, Masamichi Isobe et al.

Bone Marrow Transplantation 2018 53 :774 - 779; May 24, 2018; 10.1038/s41409-018-0217-2


Abstract | Full Text

Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry

Ana Jiménez-Ubieto, Carlos Grande, Dolores Caballero, Lucrecia Yáñez, Miguel Teodoro Hernández-Garcia et al.

Bone Marrow Transplantation 2018 53 :780 - 783; January 23, 2018; 10.1038/s41409-018-0096-6


Abstract | Full Text

Single centre results of targeted busulphan, fludarabine and serotherapy conditioning in haematopoietic stem cell transplantation for haemophagocytic lymphohistiocytosis

Stephanie Richards, Sharon Choo, Francoise Mechinaud & Theresa Cole

Bone Marrow Transplantation 2018 53 :784 - 786; March 13, 2018; 10.1038/s41409-018-0125-5


Abstract | Full Text

Refractory cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation: when should genotypic drug resistance testing be requested?

Carlos Solano, Alberto Talaya, Estela Giménez, Eliseo Albert, José Luis Piñana et al.

Bone Marrow Transplantation 2018 53 :787 - 790; April 26, 2018; 10.1038/s41409-018-0191-8


Abstract | Full Text

Depletion of donor-specific anti-HLA A2 alloantibodies in a hematopoietic cell transplant recipient using directed mismatched platelet transfusions

Bernd M. Spriewald, Christian Bach, Juergen Zingsem, Julian Strobel, Julia Winkler et al.

Bone Marrow Transplantation 2018 53 :791 - 794; May 24, 2018; 10.1038/s41409-018-0220-7


Abstract | Full Text

Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia

Katie S. Gatwood, Kathryn A. Culos, Laura A. Binari, Brian G. Engelhardt, Adetola Kassim et al.

Bone Marrow Transplantation 2018 53 :795 - 799; March 14, 2018; 10.1038/s41409-018-0124-6


Abstract | Full Text

Conventional dendritic cells are required for the cross-presentation of leukemia-specific antigen in a model of AML relapse post-BMT

Kate A. Markey, Kate H. Gartlan, Rachel D. Kuns, Steven W. Lane & Geoffrey R. Hill

Bone Marrow Transplantation 2018 53 :800 - 803; March 13, 2018; 10.1038/s41409-018-0148-y


Abstract | Full Text

Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.

Click here to sign up.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Bone Marrow Transplantation.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at: (You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: